8. Bibliografía
8. Bibliografía
1.
Albanell J, Ross J. The Epidermal growth factor receptor (EGFR) and other growth factors and receptors. En: Molecular Oncology of Breast Cancer. Jones and Bartlett Publishers. Editors Dr. G. Hortobagyi, J. Ross. 2005: 256-275
2.
Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S-40S
3.
Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. 2005: J Clin Oncol.
4.
Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005 Jul;16(7):1081-6. Epub 2005 Apr 25
5.
Cohen S 1960 Purification of a nerve growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Nat1 Acad Sci USA 1960; 46:302-311
6.
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D. and Seeburg, P. H. Nature, 1984; 309: 418-425
7.
Robinson D.R., Wu YM & Lin S.F., The protein tyrosine kinase family of the human genome. Oncogene. 2000; 19 5548-5557
8.
Moghal N. & Sternberg P.W. Multiple positive and negative regulators of signaling by EGF-receptor. Current Opinion in Cell Biology. 1999; 11 190-196
9.
Olayioye M.A., Neve R.M., Lane H.A. & Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO Journal. 2000; 19 3159-3167
10.
Lax I, Bellot F, Howk R, Ullrich A, Givol D. & Schlessinger J. Functional analysis of the ligand binding site of EGF receptor utilising chimeric chicken/human receptor molecules. EMBO Journal. 1989; 8: 421-427
11.
Prigent S.A. & Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO Journal. 1994; 13: 2831-2841
12.
Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu H-J, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW & Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell; 2002: 110 763-773
13.
Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR & Aaronson S.A. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237: 178-182
14.
Miettinen PJ, Berger JE, Meneses J et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376: 337-341.
15.
Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science. 1995;269:230-234.
16.
Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995;269:234-238.
17.
Troyer KL, Lee DC. Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 2001;6:7-21.
18.
Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
19.
Ozanne B, Richards CS, Hendler F et al. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986;149:9-14.
20.
Tang CK, Gong XQ, Moscatello DK et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 2000;60:3081-3087.
21.
Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? The Oncologist 2002; 7 (suppl 4):31-39.
22.
Sauter G, Maeda T, Waldman FM et al. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-1053.
23.
Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55: 5536-5539.
24.
Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-250.
25.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
26.
Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 1997;3:2703-2707
27.
John D.B., Yins-Nana P. et al. Validating cancer drug targets. Nature 2006; 25:451456
28.
Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer. 2001;8 :3-9
29.
Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
30.
Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J Cell Biol 1999;146:697-702.
31.
Domagala, T. et al., Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Growth Factors, 2000, 18, 11-29.
32.
Li, H. and Villalobo, A., Evidence for the direct interaction between calmodulin and the human epidermal growth factor receptor. Biochem. J., 2002, 362, 499-505.
33.
Wosikowski K, Schuurhuis D, Kops GJ et al. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. 1997;3:2405-2414.
34.
Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. 2000;59:753-767.
35.
Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 (Suppl 2): 1-13. 26.
36.
Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2000; 2: 176-183
37.
Bacus SS, Chin D, Yarden Y. et al. Type 1 receptor tyrosine kinases aredifferentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am. J. Pathol. 1996; 148: 549-558.
38.
Earp 3rd, H. S., Calvo, B. F. and Sartor, C. I., The EGF receptor family-multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans. Am. Clin. Climatol. Assoc., 2003; 114: 315-333; discussion 333-334.
39.
Harari, D. and Yarden, Y., Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 2000; 19: 6102-6114.
40.
Al Moustafa, A. E. et al., E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene, 2004; 23: 350-358.
41.
Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
42.
Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER-2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 1992; 89: 4285-4289.
43.
Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine . Cell. 1990 ; 61(2):203-12.
44.
Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648
45.
Slamon, D. J. et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344, 783-792.
46.
Pradip Nair Epidermal growth factor receptor family and its role in cancer progression. Current Science, VOL. 88, NO. 6, 25 MARCH 2005
47.
Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell. Biol. 1999;11:190-196
48.
Wells A. The epidermal growth factor receptor (EGFR)-a new target in cancer therapy. Signal. 2000;1:4-11.
49.
Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999;82:241-250.
50.
Brabender J, Danenberg KD, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer. Res. 2001;7:1850-1855
51.
Ennis BW, Lippman M.E., & Dickson R.B. The EGF receptor system as a target for antitumor therapy. Cancer Investigation. 1991; 9: 553-562
52.
Herbst R.S. & Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors:a new paradigm for cancer therapy. Cancer. 2002; 94: 1593-1611
53.
Kim E.S., Khuri F.R. & Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Current Opinion in Oncology. 2001; 13: 506-513.
54.
Goldstein NI, Prewett M, Zuklys K, Rockwell P & Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical Cancer Research. 1995; 1: 1311-1318
55.
Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI & Goldstein N.I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. Journal of Immunotherapy with Emphasis on Tumor Immunology. 1996; 19: 419-427
56.
Prewett M, Rothman M, Waksal H, Feldman M, Bander NH & Hicklin DJ 1998 Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clinical Cancer Research 4 2957-2966.
57.
Prewett M, Overholser J, Hooper A. & Waksal H.H. Growth inhibition of human pancreatic carcinoma in vitro and in vivo by chimeric anti-EGF receptor monoclonal antibody C225. Proceedings of the American Association for Cancer Research. 1999; 40: 730 Abstract 4818
58.
Huang SM & Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Investigational New Drugs. 1999; 17: 259-269
59.
Herbst R.S. & Hong W.K. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars in Oncology. 2002; 29: 18-30.
60.
Fan Z, Shang BY, Lu Y, Chou JL & Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clinical Cancer Research. 1997; 3: 1943-1948
61.
Huang S.M., Bock J.M. & Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. 1999; 59: 1935-1940
62.
Huang S.M. & Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Investigational New Drugs. 1999; 17: 259-269
63.
Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Related Cancer. 2001; 8: 3-9
64.
Viloria-Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B & Kerbel R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. 1997; 151: 1523-1530
65.
Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R & Dinney C.P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research. 1999; 5: 257-265
66.
Davis C.G., Gallo M.L. & Corvalan J.R. Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer Metastasis Reviews. 1999; 18: 421-425
67.
Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG & Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. 1999; 59: 1236-1243.
68.
Yang X.D., Jia X.C., Corvalan J.R., Wang P. & Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Critical Reviews in Oncology/Hematology. 2001; 38: 17-23
69.
Lynch D.H. & Yang X.D.Therapeutic potential of ABX-EGF:a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Seminars in Oncology. 2002; 29: 47-50.
70.
Wang P., Fredlin P., Davis C.G. & Yang X.D. Human anti-EGF receptor monoclonal antibody ABX-EGF:a potential monotherapy for the treatment of prostate cancer. Proceedings of the American Society of Clinical Oncology2003; 22: Abstract 4525.
71.
Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Research2001; 61: 5349-5354
72.
Bridges A. J., Cody D. R., Zhou H., McMichael A., Fry D. W. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-( -phenethylamino) quinazolines. Bioorg. Med. Chem. 1995; 3: 1651-1656
73.
Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science (Wash. DC)1995;, 267: 1782-1788
74.
Shugar D. Protein kinase inhibitors as potential chemotherapeutic agents. Acta Biochim. Pol. 1995; 42: 405-418
75.
Woodburn J. R., Barker A. J. 4-Anilinoquiinazolines-a potential new therapy for major human solid tumors overexpressing the EGF receptor. Br. J. Cancer, 1996; 74: 18-24
76.
Klohs W. D., Fry D. W., Kraker A. J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 1997; 9: 562-568.
77.
Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of pharmacore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 1997; 24: 3601-3616
78.
Levitt M. L., Koty P. P. Tyrosine kinase inhibitors in preclinical development. Investig. New Drugs, 1999; 17: 213-226
79.
Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 1999; 82: 231-239
80.
Traxler P., Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999; 82: 195-206
81.
Kris M. G., Herbst R., Rischin D., LoRusso P., Baselga J., Hammond L., Feyereislova A., Ochs O., Averbuch S. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer,2000; 29 (Suppl. 1): 72
82.
Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 2000; 60 (Suppl 1) 25-32
83.
Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR & Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research. 2000; 6: 2053-2063
84.
Arteaga C.L. & Johnson D.H. Tyrosine kinase inhibitors-ZD1839 (Iressa). Current Opinion in Oncology. 2001; 13: 491-498
85.
AstraZeneca Pharmaceuticals LP Iressa (gefitinib) product label.2003
86.
Woodburn JR, Kendrew J, Fennell M & Wakeling AE 2000 ZD1839 ('IRESSA') A selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI):inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proceedings of the American Association for Cancer Research. 2000; 41: 402
87.
Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson JF & Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa ) inh ib its HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Research.2001; 61: 8887-8895
88.
Sirotnak F.M. Studies with ZD1839 in preclinical models. Seminars in Oncology. 2003; 30: 12-20.
89.
Sirotnak FM, Zakowski MF, Miller VA, Scher HI & Kris MG 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clinical Cancer Research. 2000; 6: 4885-4892
90.
Albanell J., Rojo F. & Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Seminars in Oncology. 2001; 28: 56-66.
91.
Magne N., Fischel J.L., Dubreuil A., Formento P., Poupon M.F., Laurent-Puig P. & Milano G. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa '). British Journal of Cancer.2002; 86; 1518-1523.
92.
Di Gennaro E., Barbarino M., Bruzzese F., De Lorenzo S., Caraglia M., Abbruzzese A., et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa '), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. Journal of Cellular Physiology. 2003;195: 139-150
93.
Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M & Ono M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research. 2002; 62: 2554-2560
94.
Barnes C.J., Bagheri-Yarmand R., Mandal M., Yang Z., Clayman G.L., Hong W.K. & Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Molecular Cancer Therapeutics. 2003;2: 345-351
95.
Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P. et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research. 1997; 57: 4838-4848
96.
Akita R.W. & Sliwkowski M.X. Preclinical studies with Erlotinib (Tarceva). Seminars in Oncology. 2003; 30: 15-24.
97.
Iwata K.K., Provoncha K. & Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proceedings of the American Society of Clinical Oncology. 2002; 21: 21a Abstract 79 98. Jungbluth AA, Stockert E, Huang HJS, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. PNAS. 2003; 100: 639-644
© 2010 BioCancer.com